HEM Pharma (376270) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HEM Pharma (376270) reported revenue of 13.0 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202513.0 billion KRW-15.6 billion KRW-23.7 billion KRW[source]
202415.1 billion KRW-7.7 billion KRW-7.6 billion KRW[source]
20235.3 billion KRW-11.8 billion KRW-11.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202551.2 billion KRW46.1 billion KRW5.1 billion KRW[source]
202436.9 billion KRW10.7 billion KRW26.1 billion KRW[source]
202327.8 billion KRW10.4 billion KRW17.4 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-8.3 billion KRW-5.6 billion KRW21.4 billion KRW[source]
2024———[source]
2023———[source]

Cash flow figures for the relevant year were not collected.

Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice